MX2013008736A - Diseño de dominios de inmunoglobulina. - Google Patents

Diseño de dominios de inmunoglobulina.

Info

Publication number
MX2013008736A
MX2013008736A MX2013008736A MX2013008736A MX2013008736A MX 2013008736 A MX2013008736 A MX 2013008736A MX 2013008736 A MX2013008736 A MX 2013008736A MX 2013008736 A MX2013008736 A MX 2013008736A MX 2013008736 A MX2013008736 A MX 2013008736A
Authority
MX
Mexico
Prior art keywords
positions
kabat numbering
sdab
scaffold
cys
Prior art date
Application number
MX2013008736A
Other languages
English (en)
Inventor
Dae Young Kim
Jamshid Tanha
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of MX2013008736A publication Critical patent/MX2013008736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un armazón de anticuerpo de un solo dominio (sdAb) que comprende uno o más de un enlace disulfuro no canónico en la región marco (FR). El o los enlaces disulfuro no canónicos pueden formarse entre cisteínas introducidas por mutaciones en FR2 y FR3. En el caso donde el armazón de sdAb es un VH, la Cys puede introducirse en cualquiera de las posiciones 47-49 y cualquiera de las posiciones 67-71, con base en la numeración de Kabat; en un ejemplo, la Cys puede introducirse en las posiciones 49 y 69, con base en la numeración de Kabat. En el caso donde el armazón de sdAb es un VL, los residuos de Cys pueden introducirse en cualquiera de las posiciones 46-49 y cualquiera de las posiciones 62-66, con base en la numeración de Kabat; en un ejemplo, los residuos de Cys pueden introducirse en las posiciones 48 y 64, con base en la numeración de Kabat.
MX2013008736A 2011-01-28 2012-01-27 Diseño de dominios de inmunoglobulina. MX2013008736A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437174P 2011-01-28 2011-01-28
PCT/CA2012/000126 WO2012100343A1 (en) 2011-01-28 2012-01-27 Engineering of immunoglobulin domains

Publications (1)

Publication Number Publication Date
MX2013008736A true MX2013008736A (es) 2013-11-22

Family

ID=46580154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008736A MX2013008736A (es) 2011-01-28 2012-01-27 Diseño de dominios de inmunoglobulina.

Country Status (15)

Country Link
US (2) US9371371B2 (es)
EP (2) EP3587447A3 (es)
JP (2) JP6093715B2 (es)
KR (1) KR20140092237A (es)
CN (2) CN107513104A (es)
AU (1) AU2012211011A1 (es)
BR (1) BR112013019150A2 (es)
CA (1) CA2825552A1 (es)
EA (1) EA201391086A1 (es)
ES (1) ES2746559T3 (es)
IL (1) IL227656A0 (es)
MX (1) MX2013008736A (es)
RU (1) RU2013139260A (es)
SG (1) SG194472A1 (es)
WO (1) WO2012100343A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322623A3 (en) * 2005-03-25 2011-10-19 National Research Council of Canada Method for isolation of soluble polypeptides
JP6093715B2 (ja) 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
IN2015DN04087A (es) * 2012-10-24 2015-10-09 Nat Res Council Canada
BR112015024926A2 (pt) * 2013-04-16 2017-10-10 Genentech Inc composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
CA2974192C (en) * 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
UA121881C2 (uk) 2015-01-23 2020-08-10 Гелікс Байофарма Корп. Кон'югат антитіло-уреаза для терапевтичних цілей
US10421806B2 (en) * 2015-02-04 2019-09-24 Abcelex Technologies Inc. Anti-salmonella antibodies and uses thereof
AU2017293450A1 (en) * 2016-07-06 2019-02-14 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
CN109844105A (zh) 2016-07-11 2019-06-04 得克萨斯州大学***董事会 包含硒代半胱氨酸的重组多肽及其产生方法
EP3506945A4 (en) 2016-08-30 2020-07-15 Board of Regents, The University of Texas System PRODUCTION OF SELENO-BIOLOGICALS IN GENETICALLY RECODED ORGANISMS
JP7117088B2 (ja) 2017-08-04 2022-08-12 シスメックス株式会社 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
US11623965B2 (en) 2017-08-16 2023-04-11 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
EP3746480A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Bispecific antibodies comprising an antigen-binding site binding to lag3
EP3746470A1 (en) * 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
CN108191973B (zh) * 2018-03-06 2021-04-27 中国科学院武汉病毒研究所 一种靶向埃博拉病毒囊膜蛋白的高亲和力单域抗体及其制备方法与应用
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
JP2023507083A (ja) 2019-12-19 2023-02-21 クイデル コーポレーション モノクローナル抗体融合物
JP7481856B2 (ja) 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
KR20240046557A (ko) 2021-08-18 2024-04-09 하버 바이오메드 (상하이) 컴퍼니 리미티드 항-b7-h4 항체 및 이의 제조 방법과 용도
WO2024095130A1 (en) * 2022-10-31 2024-05-10 National Research Council Of Canada Improved engineered immunoglobulins and binding fragments

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
WO2003046560A2 (en) 2001-11-30 2003-06-05 National Research Council Of Canada Self-assembly molecules
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
EP2322623A3 (en) 2005-03-25 2011-10-19 National Research Council of Canada Method for isolation of soluble polypeptides
JP5092160B2 (ja) * 2007-03-08 2012-12-05 独立行政法人産業技術総合研究所 ラクダ科動物のｖｈｈドメインの安定化
CN101821288A (zh) * 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
RU2010102859A (ru) * 2007-08-21 2011-09-27 Морфосис Аг (De) Улучшенные способы образования дисульфидных связей
CN101743592B (zh) 2007-12-14 2013-03-27 Lsi公司 使用伺服数据控制飞行高度的***和方法
CN101939333A (zh) * 2007-12-21 2011-01-05 加拿大国家研究委员会 非聚集性人vh结构域
KR20110014607A (ko) * 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
JP6093715B2 (ja) 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製

Also Published As

Publication number Publication date
CN103619875B (zh) 2017-03-08
CN107513104A (zh) 2017-12-26
US9371371B2 (en) 2016-06-21
SG194472A1 (en) 2013-12-30
CA2825552A1 (en) 2012-08-02
EA201391086A1 (ru) 2014-01-30
US20170044238A1 (en) 2017-02-16
AU2012211011A1 (en) 2013-08-15
US20130303406A1 (en) 2013-11-14
EP3587447A2 (en) 2020-01-01
EP2668206B1 (en) 2019-07-17
ES2746559T3 (es) 2020-03-06
RU2013139260A (ru) 2015-03-10
EP2668206A4 (en) 2015-05-06
IL227656A0 (en) 2013-09-30
CN103619875A (zh) 2014-03-05
US10633430B2 (en) 2020-04-28
JP2014506454A (ja) 2014-03-17
JP2017079797A (ja) 2017-05-18
EP3587447A3 (en) 2020-05-13
KR20140092237A (ko) 2014-07-23
WO2012100343A1 (en) 2012-08-02
EP2668206A1 (en) 2013-12-04
JP6093715B2 (ja) 2017-03-08
BR112013019150A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
SG194472A1 (en) Engineering of immunoglobulin domains
MY187741A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
EP3470427A4 (en) MONOCLONAL INTERLEUKIN-17A HUMAN ANTIBODIES, PREPARATION METHOD AND USE THEREOF
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
NZ627260A (en) Cx3cr1-binding polypeptides
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2012022982A3 (en) Improved antibodies of the class igg4
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EP3426686A4 (en) HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EP3389699A4 (en) HUMAN ANTI-CTLA4 CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES AND USES THEREOF
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
SG10201901057UA (en) Anti-pd-l1 antibodies
WO2015138615A3 (en) Specific sites for modifying antibodies to make immunoconjugates
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EP3466974A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-1 ANTIBODIES AND ITS USE
NZ586357A (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2015013389A3 (en) Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1
EP3565596A4 (en) PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
EP3684369A4 (en) A33-ANTIBODY COMPOSITIONS AND METHOD OF USING THEREOF IN RADIOIMMUNOTHERAPY
MX2014010021A (es) Anticuerpos biespecificos igg4 modificados de secuencia asimetrica.
WO2011131786A3 (en) Process for preparing an immunoglobulin composition
WO2014124258A3 (en) Specific sites for modifying antibodies to make immunoconjugates
WO2013009521A3 (en) Methods and compositions for treating asthma using anti-il-13 antibodies
EP3573658A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal